About this Calculator
This Evenity (romosozumab) Dosing Calculator is designed to help healthcare professionals map out the complete 12-month treatment course for patients with osteoporosis. By providing a start date or the date of the last administered dose, the tool generates a clear, monthly dosing schedule according to the FDA-approved regimen, simplifying treatment planning and patient counseling.
Outputs Explained
After entering a valid date, the calculator provides the following key information:
- Next Dose Date: Clearly indicates the date the next monthly dose is due, which is particularly useful when calculating from the last administered dose.
- Full Dosing Schedule: A comprehensive table detailing the scheduled administration date for all 12 monthly doses of the treatment course.
- Administration Summary: A reminder of the total monthly dose (210 mg) and the method of administration (two separate 105 mg subcutaneous injections).
How to Use the Tool
To generate a dosing schedule, follow these simple steps:
- Select a Date: Use the date picker to choose a relevant date.
- Specify Date Type: Indicate whether the selected date is the planned "Treatment Start Date" or the "Date of Last Administered Dose."
- Calculate: Click the "Calculate Schedule" button to generate the complete 12-month plan and see the next due date.
Dosing Overview
Evenity (romosozumab) Dosing Regimen
- Total Monthly Dose: 210 mg administered once monthly.
- Administration: The 210 mg dose is given as two separate 105 mg subcutaneous injections, one immediately following the other, at different injection sites.
- Treatment Duration: The total duration of therapy is limited to 12 monthly doses.
- Supplementation: Patients should be advised to take calcium and vitamin D supplements during treatment if their dietary intake is inadequate.
Switching Therapy After Evenity
Transitioning to Antiresorptive Therapy
Evenity is an anabolic agent that stimulates bone formation. To maintain the bone mineral density gains achieved, patients should be transitioned to an antiresorptive agent (such as a bisphosphonate or denosumab) upon completion of the 12-month Evenity course. This sequential therapy approach is critical for long-term fracture risk reduction.
Missed Dose Protocol
Guidance for Missed Doses
If a patient misses a scheduled dose of Evenity, the dose should be administered as soon as it can be rescheduled. The next dose should then be scheduled every month from the date of this last administered dose. The calculator's "Date of Last Administered Dose" option is designed to help recalculate the schedule based on this scenario.
Safety Alerts
BLACK BOX WARNING: Cardiovascular Risk
Evenity may increase the risk of myocardial infarction, stroke, and cardiovascular death. It is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year. A benefit-risk assessment is necessary for patients with other cardiovascular risk factors. Therapy should be discontinued if a patient experiences a myocardial infarction or stroke.
Other Important Safety Information
- Hypocalcemia: Pre-existing hypocalcemia must be corrected prior to initiating Evenity. Serum calcium levels should be monitored.
- Osteonecrosis of the Jaw (ONJ): ONJ has been reported in patients receiving Evenity. A routine oral examination should be performed by the prescriber prior to starting therapy.
- Atypical Femoral Fractures: Atypical low-energy or low-trauma fractures of the femoral shaft have been reported.
Frequently Asked Questions
Why must Evenity be given as two separate injections?
The total 210 mg dose is formulated at a concentration of 105 mg/1.17 mL. Delivering this dose requires two prefilled syringes to administer the full therapeutic amount comfortably via subcutaneous injection.
Can I use this calculator if a dose was missed by several weeks?
Yes. Select the "Date of Last Administered Dose" option and input the date the make-up dose was given. The tool will correctly project the new 12-month schedule starting from that date.
What happens if a calculated dose date falls on a weekend or holiday?
The generated dates are exactly one month apart. Clinical judgment should be used to schedule the administration on a nearby business day. Minor adjustments of a few days are not expected to impact efficacy.
Does the 12-month treatment course ever reset?
No. The total lifetime exposure to Evenity is limited to 12 monthly doses. The calculator maps out a single 12-month course and should not be used to plan for re-treatment.
Where on the body can Evenity be injected?
Evenity should be administered subcutaneously in the abdomen, thigh, or upper arm. The two injections should be given at different anatomic sites.
Is a dose adjustment needed for patients with renal impairment?
No dose adjustment is necessary for patients with renal impairment. However, patients with severe renal impairment or on dialysis are at greater risk for hypocalcemia and should be monitored.
Who can administer the Evenity injections?
Evenity should be administered by a healthcare professional. It is not intended for patient self-administration.
What if my patient experiences a stroke during therapy?
Per the Black Box Warning, Evenity should be discontinued immediately if a patient experiences a myocardial infarction or stroke during the treatment course.
References
- EVENITY (romosozumab-aqqg) Prescribing Information. U.S. Food and Drug Administration.
- Evenity HCP Official Website. Amgen Inc. and UCB, Inc.
- Saag KG, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417-1427. doi:10.1056/NEJMoa1708322
- Camacho PM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46. doi:10.4158/GL-2020-0524
This information is intended for educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always consult the official Prescribing Information and exercise clinical judgment.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com